Scott Cramer, PhD
Professor, Pharmacology

Publications

• Jillson LK, Yette GA, Laajala TD, Tilley WD, Costello JC, Cramer SD. Androgen Receptor Signaling in Prostate Cancer Genomic Subtypes. Cancers (Basel). 2021 Jun 30;13(13). PubMed PMID: 34208794
• Jillson LK, Rider LC, Rodrigues LU, Romero L, Karimpour-Fard A, Nieto C, Gillette C, Torkko K, Danis E, Smith EE, Nolley R, Peehl DM, Lucia MS, Costello JC, Cramer SD. MAP3K7 Loss Drives Enhanced Androgen Signaling and Independently Confers Risk of Recurrence in Prostate Cancer with Joint Loss of CHD1 . Mol Cancer Res. 2021 Jul;19(7):1123-1136. PubMed PMID: 33846123
• Bayne RS, Puckett S, Rodrigues LU, Cramer SD, Lee J, Furdui CM, Chou JW, Miller LD, Ornelles DA, Lyles DS. MAP3K7 and CHD1 Are Novel Mediators of Resistance to Oncolytic Vesicular Stomatitis Virus in Prostate Cancer Cells. Mol Ther Oncolytics. 2020 Jun 26;17:496-507. PubMed PMID: 32529027
• Miller DR, Cramer SD, Thorburn A. The interplay of autophagy and non-apoptotic cell death pathways. Int Rev Cell Mol Biol. 2020;352:159-187. PubMed PMID: 32334815
• Ormond DR, Kleinschmidt-DeMasters BK, Cavalcante D, Smith EE, Cramer SD, Lucia MS. Prostatic adenocarcinoma CNS parenchymal and dural metastases: alterations in ERG, CHD1 and MAP3K7 expression. J Neurooncol. 2019 Jan 17. [Epub ahead of print] PubMed PMID: 30656528
• Washino S, Rider LC, Romero L, Jillson LK, Affandi T, Ohm AM, Lam ET, Reyland ME, Costello JC, Cramer SD. Loss of MAP3K7 Sensitizes Prostate Cancer Cells to CDK1/2 Inhibition and DNA Damage by Disrupting Homologous Recombination. Mol Cancer Res. 2019 Oct;17(10):1985-1998. PubMed PMID: 31300540
• Ormond DR, Kleinschmidt-DeMasters BK, Cavalcante D, Smith EE, Cramer SD, Lucia MS. Prostatic adenocarcinoma CNS parenchymal and dural metastases: alterations in ERG, CHD1 and MAP3K7 expression. J Neurooncol. 2019 Apr;142(2):319-325. PubMed PMID: 30656528
• Chmielewski JP, Bowlby SC, Wheeler FB, Shi L, Sui G, Davis AL, Howard TD, D'Agostino RB Jr, Miller LD, Sirintrapun SJ, Cramer SD, Kridel SJ. CD38 Inhibits Prostate Cancer Metabolism and Proliferation by Reducing Cellular NAD( ) Pools. Mol Cancer Res. 2018 Nov;16(11):1687-1700. PubMed PMID: 30076241
• Goodall ML, Cramer SD, Thorburn A. Autophagy RIPs into cell death. Cell Cycle. 2016 Nov 16;15(22):3014-3015. PubMed PMID: 27574850
• Goodall ML, Cramer SD, Thorburn A. Autophagy complexes cell death by necroptosis. Oncotarget. 2016 Aug 9;7(32):50818-50819. PubMed PMID: 27449298
• Goodall ML, Fitzwalter BE, Zahedi S, Wu M, Rodriguez D, Mulcahy-Levy JM, Green DR, Morgan M, Cramer SD, Thorburn A. The Autophagy Machinery Controls Cell Death Switching between Apoptosis and Necroptosis. Dev Cell. 2016 May 23;37(4):337-49. PubMed PMID: 27219062
• Schlaepfer IR, Rider L, Rodrigues LU, Gijón MA, Pac CT, Romero L, Cimic A, Sirintrapun SJ, Glodé LM, Eckel RH, Cramer SD. Lipid catabolism via CPT1 as a therapeutic target for prostate cancer. Mol Cancer Ther. 2014 Oct;13(10):2361-71. PubMed PMID: 25122071
• Nieto CM, Rider LC, Cramer SD. Influence of stromal-epithelial interactions on androgen action. Endocr Relat Cancer. 2014 Aug;21(4):T147-60. PubMed PMID: 24872510
• Ting HJ, Deep G, Jain AK, Cimic A, Sirintrapun J, Romero LM, Cramer SD, Agarwal C, Agarwal R. Silibinin prevents prostate cancer cell-mediated differentiation of naïve fibroblasts into cancer-associated fibroblast phenotype by targeting TGF ß2. Mol Carcinog. 2014 Feb 24. [Epub ahead of print] PubMed PMID: 24615813
• Maund SL, Shi L, Cramer SD. A role for interleukin-1 alpha in the 1,25 dihydroxyvitamin D3 response in mammary epithelial cells. PLoS One. 2013;8(11):e81367. PubMed PMID: 24244740
• Liu W, Xie CC, Thomas CY, Kim ST, Lindberg J, Egevad L, Wang Z, Zhang Z, Sun J, Sun J, Koty PP, Kader AK, Cramer SD, Bova GS, Zheng SL, Grönberg H, Isaacs WB, Xu J. Genetic markers associated with early cancer-specific mortality following prostatectomy. Cancer. 2013 Jul 1;119(13):2405-12. PubMed PMID: 23609948